CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Zacks12-11

Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib (20 mg and 30 mg), in combination with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490862493?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","is_english":true,"pubTime":"2024-12-11 23:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490862493","market":"us","top_or_hot":-1,"title":"CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study","media":"Zacks","content":"<div>\n<p>Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib (20 mg and 30 mg), in combination with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/crdf-stock-soars-robust-efficacy-150500661.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/crdf-stock-soars-robust-efficacy-150500661.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib (20 mg and 30 mg), in combination with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/crdf-stock-soars-robust-efficacy-150500661.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFS","symbol_name":"Provident Financial Services Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/crdf-stock-soars-robust-efficacy-150500661.html","article_id":"2490862493","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490862493","pubTimestamp":1733929500,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Cardiff OncologyCRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib , in combination with standard-of-care  chemotherapy to treat first-line RAS-mutated metastatic colorectal cancer  patients. The stock rallied 54.9% on Tuesday following the encouraging news. The primary endpoint of the study was objective response rate , and the secondary endpoints included progression-free survival , duration of response and safety.Per the data from the phase II CRDF-004 study, treatment with the 30 mg dose of onvansertib, a PLK1 inhibitor, demonstrated an ORR of 64%, almost double the 33% ORR observed in the control arm . The 30 mg dose arm also demonstrated a higher ORR compared with the 50% ORR observed in the 20 mg dose arm. Overall, patients treated with onvansertib demonstrated an ORR of 57%.The company also shared spider plots in the press release which show that patients receiving the 30mg dose of onvanser","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFS":"Provident Financial Services Inc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4550":"红杉资本持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4599":"减肥药","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4578":"CAR-T","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4195":"互助储蓄与抵押信贷金融服务","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999002232.USD":"Allianz Global High Payout USD","SOC":"Sable Offshore Corp.","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4581":"高盛持仓","PFE":"辉瑞","GILD":"吉利德科学","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4213":"石油与天然气的勘探与生产","CRDF":"Cardiff Oncology, Inc.","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","ALNY":"阿尔尼拉姆制药公司","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC"},"translate_title":"CRDF股价因结直肠癌研究的强劲疗效数据而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOC":1,"ALNY":1,"PFS":1,"CRDF":1,"GILD":1,"PFE":0.9},"content_text":"Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib (20 mg and 30 mg), in combination with standard-of-care (SOC) chemotherapy to treat first-line RAS-mutated metastatic colorectal cancer (mCRC) patients. The stock rallied 54.9% on Tuesday following the encouraging news. The primary endpoint of the study was objective response rate (ORR), and the secondary endpoints included progression-free survival (PFS), duration of response and safety.\nPer the data from the phase II CRDF-004 study, treatment with the 30 mg dose of onvansertib, a PLK1 inhibitor, demonstrated an ORR of 64%, almost double the 33% ORR observed in the control arm (SOC alone). The 30 mg dose arm also demonstrated a higher ORR compared with the 50% ORR observed in the 20 mg dose arm. Overall, patients treated with onvansertib demonstrated an ORR of 57%.\nThe company also shared spider plots in the press release which show that patients receiving the 30mg dose of onvansertib with SOC experienced greater tumor size reduction over time compared to those in the control and 20mg dose arms with similar safety profiles for both doses. The combo therapy was also well tolerated in the CRDF-004 study with no major or unexpected toxicities observed.\nBased on the encouraging data readout, management believes that onvansertib has the potential to revolutionize the treatment paradigm for the first-line RAS-mutated mCRC patient population. Approximately 50,000 new patients with this mCRC indication are diagnosed in the United States, annually.\nIn the past three months, shares of Cardiff Oncology have rallied 47.7% against the industry’s 6.2% decline.\nImage Source: Zacks Investment Research\nCRDF’s Next Steps in Onvansertib Development for mCRC\nCardiff Oncology expects to share additional clinical updates from the mid-stage study in the first half of 2025. Subject to positive results from the phase II CRDF-004 study, Cardiff plans to initiate a phase III CRDF-005 registrational study for the onvansertib/SOC combo to treat patients with first-line RAS-mutated mCRC.\nFurthermore, the FDA has also agreed with the company that an interim analysis of ORR in the planned registrational study can provide the basis for an application seeking approval for the onvansertib/SOC combo under an accelerated pathway. Under such circumstances, PFS and overall survival data will be designated as endpoints for full approval.\nWe note that last year, Cardiff discontinued its phase II ONSEMBLE study evaluating onvansertib in combination with SOC therapy to treat patients with second-line RAS-mutated mCRC. The strategic decision was taken to focus the company's resources on its phase II CRDF-004 study in the first-line setting, where there is a higher unmet need.\nBesides the mCRC indication, Cardiff Oncology is also currently evaluating the safety and preliminary efficacy of onvansertib in combination with Onyvide (nanoliposomal irinotecan), fluorouracil and leucovorin in a phase II CRDF-001 study to treat second-line patients with metastatic pancreatic ductal adenocarcinoma.\nCRDF Issues Underwritten Offering to Raise Funds for Operations\nIn a separate press release, Cardiff Oncology announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions.\nThe company expects to raise approximately $40 million in gross proceeds from the underwritten offering. Net proceeds, after deducting underwriting discounts and commissions and offering expenses, will be used to fund clinical costs for onvansertib in first-line RAS-mutated mCRC and for working capital and other general corporate purposes.\nThe transaction is expected to close on Dec. 11, 2024, subject to the fulfillment of certain customary conditions.\n\nCardiff Oncology, Inc. Price and Consensus\n\nCardiff Oncology, Inc. price-consensus-chart | Cardiff Oncology, Inc. Quote\n\nCRDF’s Zacks Rank and Stocks to Consider\nCardiff Oncology currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the drug/biotech industryare Alnylam Pharmaceuticals ALNY, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nOver the past 60 days, Alnylam Pharmaceuticals’ loss estimates have narrowed from 42 cents to 39 cents per share for 2024, while that for 2025 has narrowed from 47 cents to 13 cents. ALNY shares have lost 3% in the past three months.\nAlnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 65.67%.\nIn the past 60 days, Pfizer’s earnings estimates have risen from $2.66 to $2.92 per share for 2024, while that for 2025 has increased from $2.86 to $2.94. PFE shares have lost 12.4% in the past three months.\nPfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.\nIn the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.78 to $4.29 per share for 2024, while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 10.9% in the past three months.\nGilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nGilead Sciences, Inc. (GILD) : Free Stock Analysis Report\nCardiff Oncology, Inc. (CRDF) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490862493"}